BRANFORD, Conn. / Nov 01, 2023 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in two upcoming investor conferences:
About the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
Quantum-Si management will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place at the Westin NY Grand Central on Thursday, November 16, 2023.
Jeff Hawkins, Chief Executive Officer of Quantum-Si, will participate in a fireside chat on Thursday, November 16, at 4:30 – 4:55 p.m. Eastern Time.
About the 6th Annual Evercore ISI HealthCONx Conference
Quantum-Si management will attend the 6th Annual Evercore ISI HealthCONx Conference, taking place at the Kimpton Epic Hotel in Miami, Florida on November 28-30, 2023.
Jeff Hawkins will participate in a fireside chat on Wednesday, November 29, at 7:55 – 8:15 a.m. Eastern Time.
Where to View
A live and archived webcast of both events will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com.
| Last Trade: | US$2.30 |
| Daily Change: | 0.10 4.55 |
| Daily Volume: | 11,532,805 |
| Market Cap: | US$419.890M |
September 23, 2025 September 08, 2025 August 05, 2025 June 17, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
